Trial Profile

BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cangrelor (Primary)
Indications Coronary thrombosis
Focus Registrational; Therapeutic Use
Acronyms BRIDGE
Sponsors The Medicines Company

Most Recent Events

14 Nov 2014 The Medicines Company plans to resubmit an NDA for cangrelor by the end of 2014 with respect to the PCI indication, according to a media release.
14 Nov 2014 The NDA filing was based on data from the CHAMPION PHOENIX, CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE, according to a media release from the The Medicines Company.
18 Jan 2012 Primary endpoint 'Platelet-aggregation' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com